乐普生物-B（股票代码：02157）预计2025财年业绩将显著改善，主要得益于其核心产品普佑恒（Puyouheng）与美佑恒（Meiyouheng）在获得国家药品监督管理局（NMPA）批准后，自2025年10月起带来的收入增长。此外，公司其他业务板块也有望在财年内提供额外业绩支撑。
乐普生物-B（股票代码：02157）预计2025财年业绩将显著改善，主要得益于其核心产品普佑恒（Puyouheng）与美佑恒（Meiyouheng）在获得国家药品监督管理局（NMPA）批准后，自2025年10月起带来的收入增长。此外，公司其他业务板块也有望在财年内提供额外业绩支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.